Submission Guidelines and Process


Submissions are due on or before January 31, 2017 via the submission form.

We encourage pre-submitting by sending entries before December 16th, 2016, to receive feedback and the opportunity to re-submit ahead of the final deadline.

Each submission will be reviewed as it is submitted, up until the deadline. Applicants are encouraged to submit their ideas as soon as they are ready.

Submissions must be brief and clear. They should be submitted as a PDF no longer than three pages, plus any appendices or citations an applicant deems relevant. Applicants are encouraged to review the case study section before making a submission.

Applications will be judged on the following criteria:

  • Inclusion of at least one US prescription medication.
  • A strong scientific basis for hypothesis.
  • Level of seriousness of potential interaction.
  • Proposed quantifiable clinical/non-clinical ways to test the hypothesis.
  • Originality: the hypothesis must not have been directly studied or currently addressed on a US drug label.
  • Finalists should expect to receive notification by mid-February 2017.